Hostname: page-component-848d4c4894-x5gtn Total loading time: 0 Render date: 2024-05-29T09:11:23.164Z Has data issue: false hasContentIssue false
  • English
  • Français

Modafinil and cognitive enhancement in schizophrenia and healthy volunteers: the effects of test battery in a randomised controlled trial

Published online by Cambridge University Press:  03 May 2017

J. Lees ,
P. G. Michalopoulou ,
S. W. Lewis ,
S. Preston ,
C. Bamford ,
T. Collier ,
A. Kalpakidou ,
T. Wykes ,
R. Emsley  and
G. Pandina
...Show all authors
J. Lees*
Affiliation:
Division of Psychology & Mental Health, School of Health Sciences, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK
P. G. Michalopoulou
Affiliation:
Institute of Psychiatry, Psychology and Neuroscience, King's Health Partners, London, UK
S. W. Lewis
Affiliation:
Division of Psychology & Mental Health, School of Health Sciences, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK
S. Preston
Affiliation:
Division of Psychology & Mental Health, School of Health Sciences, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK
C. Bamford
Affiliation:
Division of Psychology & Mental Health, School of Health Sciences, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK
T. Collier
Affiliation:
Institute of Psychiatry, Psychology and Neuroscience, King's Health Partners, London, UK
A. Kalpakidou
Affiliation:
Institute of Psychiatry, Psychology and Neuroscience, King's Health Partners, London, UK
T. Wykes
Affiliation:
Institute of Psychiatry, Psychology and Neuroscience, King's Health Partners, London, UK
R. Emsley
Affiliation:
Division of Population Health, Health Services Research & Primary Care, School of Health Sciences, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK
G. Pandina
Affiliation:
Janssen Research & Development, LLC, New Brunswick, New Jersey, USA
S. Kapur
Affiliation:
Institute of Psychiatry, Psychology and Neuroscience, King's Health Partners, London, UK
R. J. Drake
Affiliation:
Division of Psychology & Mental Health, School of Health Sciences, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK
*
*Address for correspondence: J. Lees, Division of Psychology & Mental Health, IBBMH, School of Health Sciences, University of Manchester, Manchester Academic Health Science Centre, Jean McFarlane Building, Oxford Rd, Manchester, M13 9PL, UK. (Email: jane.lees@manchester.ac.uk)
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Cognitive deficits in schizophrenia have major functional impacts. Modafinil is a cognitive enhancer whose effect in healthy volunteers is well-described, but whose effects on the cognitive deficits of schizophrenia appear to be inconsistent. Two possible reasons for this are that cognitive test batteries vary in their sensitivity, or that the phase of illness may be important, with patients early in their illness responding better.

Methods

A double-blind, randomised, placebo-controlled single-dose crossover study of modafinil 200 mg examined this with two cognitive batteries [MATRICS Consensus Cognitive Battery (MCCB) and Cambridge Neuropsychological Test Automated Battery (CANTAB)] in 46 participants with under 3 years’ duration of DSM-IV schizophrenia, on stable antipsychotic medication. In parallel, the same design was used in 28 age-, sex-, and education-matched healthy volunteers. Uncorrected p values were calculated using mixed effects models.

Results

In patients, modafinil significantly improved CANTAB Paired Associate Learning, non-significantly improved efficiency and significantly slowed performance of the CANTAB Stockings of Cambridge spatial planning task. There was no significant effect on any MCCB domain. In healthy volunteers, modafinil significantly increased CANTAB Rapid Visual Processing, Intra-Extra Dimensional Set Shifting and verbal recall accuracy, and MCCB social cognition performance. The only significant differences between groups were in MCCB visual learning.

Conclusions

As in earlier chronic schizophrenia studies, modafinil failed to produce changes in cognition in early psychosis as measured by MCCB. CANTAB proved more sensitive to the effects of modafinil in participants with early schizophrenia and in healthy volunteers. This confirms the importance of selecting the appropriate test battery in treatment studies of cognition in schizophrenia.

Keywords

CANTABcognitionMATRICS MCCBmodafinilschizophrenia
Type
Original Articles
Information
Psychological Medicine , Volume 47 , Issue 13 , October 2017 , pp. 2358 - 2368
Copyright
Copyright © Cambridge University Press 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Battleday, RM, Brem, AK (2015). Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: a systematic review. European Neuropsychopharmacology 25, 1865–1881.CrossRefGoogle ScholarPubMed
Brekke, JS, Hoe, M, Green, MF (2009). Neurocognitive change, functional change and service intensity during community-based psychosocial rehabilitation for schizophrenia. Psychological Medicine 39, 10.Google Scholar
Cannon, TD, Zorrilla, LE, Shtasel, D, Gur, RE, Gur, RC, Marco, EJ, Moberg, P, Price, RA (1994). Neuropsychological functioning in siblings discordant for schizophrenia and healthy volunteers. Archives of General Psychiatry 51, 651–661.Google Scholar
Caspi, A, Reichenberg, A, Weiser, M, Rabinowitz, J, Kaplan, Z, Knobler, H, Davidson-Sagi, N, Davidson, M (2003). Cognitive performance in schizophrenia patients assessed before and following the first psychotic episode. Schizophrenia Research 65, 87–94.CrossRefGoogle ScholarPubMed
Censits, DM, Ragland, JD, Gur, RC, Gur, RE (1997). Neuropsychological evidence supporting a neurodevelopmental model of schizophrenia: a longitudinal study. Schizophrenia Research 24, 289–298.Google Scholar
De Rover, M, Pironti, VA, Mccabe, JA, Acosta-Cabronero, J, Arana, FS, Morein-Zamir, S, Hodges, JR, Robbins, TW (2011). Hippocampal dysfunction in patients with mild cognitive impairment: a functional neuroimaging study of a visuospatial paired associates learning task. Neuropsychologia 49, 2060–2070.CrossRefGoogle ScholarPubMed
Gerrard, P, Malcolm, R (2007). Mechanisms of modafinil: a review of current research. Neuropsychiatric Disease and Treatment 3, 349–364.Google ScholarPubMed
Goldberg, TE, Ragland, JD, Torrey, EF, Gold, JM, Bigelow, LB, Weinberger, DR (1990). Neuropsychological assessment of monozygotic twins discordant for schizophrenia. Archives of General Psychiatry 47, 1066–1072.Google Scholar
Green, MF (1996). What are the functional consequences of neurocognitive deficits in schizophrenia? American Journal of Psychiatry 153, 321–330.Google Scholar
Harvey, PD, Bowie, CR, Friedman, JI (2001). Cognition in schizophrenia. Current Psychiatry Reports 3, 423–428.CrossRefGoogle ScholarPubMed
Hoe, M, Nakagami, E, Green, MF, Brekke, JS (2012). The causal relationships between neurocognition, social cognition and functional outcome over time in schizophrenia: a latent difference score approach. Psychological Medicine 42, 2287–2299.CrossRefGoogle ScholarPubMed
Holdnack, H (2001). Wechsler Test of Adult Reading: WTAR. Harcourt Assessment: San Antonio, TX.Google Scholar
Hunter, MD, Ganesan, V, Wilkinson, ID, Spence, SA (2006). Impact of modafinil on prefrontal executive function in schizophrenia. American Journal of Psychiatry 163, 2184–2186.CrossRefGoogle ScholarPubMed
Irani, F, Brensinger, CM, Richard, J, Calkins, ME, Moberg, PJ, Bilker, W, Gur, RE, Gur, RC (2012). Computerized neurocognitive test performance in schizophrenia: a lifespan analysis. American Journal of Geriatric Psychiatry 20, 41–52.Google Scholar
Joo, EY, Tae, WS, Jung, KY, Hong, SB (2008). Cerebral blood flow changes in man by wake-promoting drug, modafinil: a randomized double blind study. Journal of Sleep Research 17, 82–88.CrossRefGoogle Scholar
Joyce, EM (2013). Cognitive function in schizophrenia: insights from intelligence research. British Journal of Psychiatry 203, 161–162.Google Scholar
Kaser, M, Deakin, JB, Michael, A, Zapata, C, Bansal, R, Ryan, D, Cormack, F, Rowe, JB, Sahakian, BJ (2017). Modafinil improves episodic memory and working memory cognition in patients with remitted depression: a double-blind, randomized, placebo-controlled study. Biological Psychiatry 2, 115–122.Google Scholar
Kern, RS, Nuechterlein, KH, Green, MF, Baade, LE, Fenton, WS, Gold, JM, Keefe, RS, Mesholam-Gately, R, Mintz, J, Seidman, LJ, Stover, E, Marder, SR (2008). The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. American Journal of Psychiatry 165, 214–220.Google Scholar
Lees, J, Applegate, E, Emsley, R, Lewis, S, Michalopoulou, P, Collier, T, Lopez-Lopez, C, Kapur, S, Pandina, G, Drake, R (2015). Calibration and cross-validation of MCCB and CogState in schizophrenia. Psychopharmacology (Berl) 232, 3873–3882.Google Scholar
Michalopoulou, PG, Lewis, SW, Drake, RJ, Reichenberg, A, Emsley, R, Kalpakidou, AK, Lees, J, Bobin, T, Gilleen, JK, Pandina, G, Applegate, E, Wykes, T, Kapur, S (2015). Modafinil combined with cognitive training: pharmacological augmentation of cognitive training in schizophrenia. European Neuropsychopharmacology 25, 1178–1189.CrossRefGoogle ScholarPubMed
Minzenberg, MJ, Laird, AR, Thelen, S, Carter, CS, Glahn, DC (2009). Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. Archives of General Psychiatry 66, 811–822.Google Scholar
Mohamed, AD, Lewis, CR (2014). Modafinil increases the latency of response in the Hayling Sentence Completion Test in healthy volunteers: a randomised controlled trial. PLoS ONE 9, e110639.Google Scholar
Müller, U, Rowe, JB, Rittman, T, Lewis, C, Robbins, TW, Sahakian, BJ (2013). Effects of modafinil on non-verbal cognition, task enjoyment and creative thinking in healthy volunteers. Neuropharmacology 64, 490–495.CrossRefGoogle ScholarPubMed
Nuechterlein, KH, Green, MF, Kern, RS, Baade, LE, Barch, DM, Cohen, JD, Essock, S, Fenton, WS, Frese, FJ III, Gold, JM, Goldberg, T, Heaton, RK, Keefe, RS, Kraemer, H, Mesholam-Gately, R, Seidman, LJ, Stover, E, Weinberger, DR, Young, AS, Zalcman, S, Marder, SR (2008). The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity. American Journal of Psychiatry 165, 203–213.CrossRefGoogle ScholarPubMed
Pierre, JM, Peloian, JH, Wirshing, DA, Wirshing, WC, Marder, SR (2007). A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia. Journal of Clinical Psychiatry 68, 705–710.Google Scholar
Randall, DC, Fleck, NL, Shneerson, JM, File, SE (2004). The cognitive-enhancing properties of modafinil are limited in non-sleep-deprived middle-aged volunteers. Pharrmacology, Biochemistry and Behavior 77, 547–555.CrossRefGoogle ScholarPubMed
Randall, DC, Shneerson, JM, File, SE (2005 a). Cognitive effects of modafinil in student volunteers may depend on IQ. Pharrmacology, Biochemistry and Behavior 82, 133–139.CrossRefGoogle ScholarPubMed
Randall, DC, Shneerson, JM, Plaha, KK, File, SE (2003). Modafinil affects mood, but not cognitive function, in healthy young volunteers. Human Psychopharmacology 18, 163–173.Google Scholar
Randall, DC, Viswanath, A, Bharania, P, Elsabagh, SM, Hartley, DE, Shneerson, JM, File, SE (2005 b). Does modafinil enhance cognitive performance in young volunteers who are not sleep-deprived? Journal of Clinical Psychopharmacology 25, 175–179.CrossRefGoogle Scholar
Reichenberg, A, Caspi, A, Harrington, H, Houts, R, Keefe, RS, Murray, RM, Poulton, R, Moffitt, TE (2010). Static and dynamic cognitive deficits in childhood preceeding adult schizophrenia: a 30-year study. American Journal of Psychiatry 167, 160–169.Google Scholar
Robbins, TW, James, M, Owen, AM, Sahakian, BJ, Lawrence, AD, Mcinnes, L, Rabbitt, PM (1998). A study of performance on tests from the CANTAB battery sensitive to frontal lobe dysfunction in a large sample of normal volunteers: implications for theories of executive functioning and cognitive aging. Cambridge Neuropsychological Test Automated Battery. Journal of the International Neuropsychological Society 4, 474–490.CrossRefGoogle Scholar
Robbins, TW, James, M, Owen, AM, Sahakian, BJ, Mcinnes, L, Rabbitt, P (1994). Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers. Dementia 5, 266–281.Google Scholar
Rosenthal, MH, Bryant, SL (2004). Benefits of adjunct modafinil in an open-label, pilot study in patients with schizophrenia. Clinical Neuropharmacology 27, 38–43.Google Scholar
Rothman, K (1990). No adjustments are needed for multiple comparisons. Epidemiology 1, 43–46.Google Scholar
Scoriels, L, Barnett, JH, Murray, GK, Cherukuru, S, Fielding, M, Cheng, F, Lennox, BR, Sahakian, BJ, Jones, PB (2011). Effects of modafinil on emotional processing in first episode psychosis. Biological Psychiatry 69, 457–464.Google Scholar
Scoriels, L, Barnett, JH, Soma, PK, Sahakian, BJ, Jones, PB (2012). Effects of modafinil on cognitive functions in first episode psychosis. Psychopharmacology (Berl) 220, 249–258.Google Scholar
Scoriels, L, Jones, PB, Sahakian, BJ (2013). Modafinil effects on cognition and emotion in schizophrenia and its neurochemical modulation in the brain. Neuropharmacology 64, 168–184.Google Scholar
Sevy, S, Rosenthal, MH, Alvir, J, Meyer, S, Visweswaraiah, H, Gunduz-Bruce, H, Schooler, NR (2005). Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. Journal of Clinical Psychiatry 66, 839–843.Google Scholar
Sheehan, DV, Lecrubier, Y, Sheehan, KH, Amorim, P, Janavs, J, Weiller, E, Hergueta, T, Baker, R, Dunbar, GC (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry 59(Suppl 20), 22–33; quiz 34–57.Google Scholar
Spence, SA, Green, RD, Wilkinson, ID, Hunter, MD (2005). Modafinil modulates anterior cingulate function in chronic schizophrenia. British Journal of Psychiatry 187, 55–61.Google Scholar
Turner, DC, Clark, L, Pomarol-Clotet, E, Mckenna, P, Robbins, TW, Sahakian, BJ (2004). Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology 29, 1363–1373.Google Scholar
Turner, DC, Robbins, TW, Clark, L, Aron, AR, Dowson, J, Sahakian, BJ (2003). Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology (Berl) 165, 260–269.Google Scholar
Vreeker, A, Van Bergen, AH, Kahn, RS (2015). Cognitive enhancing agents in schizophrenia and bipolar disorder. European Neuropsychopharmacology 25, 969–1002.Google Scholar
Winder-Rhodes, SE, Chamberlain, SR, Idris, MI, Robbins, TW, Sahakian, BJ, Müller, U (2010). Effects of modafinil and prazosin on cognitive and physiological functions in healthy volunteers. Journal of Psychopharmacology 24, 1649–1657.CrossRefGoogle ScholarPubMed
Wong, YN, King, SP, Simcoe, D, Gorman, S, Laughton, W, Mccormick, GC, Grebow, P (1999 a). Open-label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects. Journal of Clinical Pharmacology 39, 281–288.CrossRefGoogle ScholarPubMed
Wong, YN, Simcoe, D, Hartman, LN, Laughton, WB, King, SP, Mccormick, GC, Grebow, PE (1999 b). A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. Journal of Clinical Pharmacology 39, 30–40.Google Scholar
Supplementary material: PDF

Lees supplementary material

Tables S1-S7

Download Lees supplementary material(PDF)
PDF 530.2 KB